Treatment
Baricitinib clinical trials
We’re tracking 32 recruiting studies that include Baricitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07279688RecruitingPhase 3
Baricitinib plus steroids for polymyalgia rheumatica
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
Aix-en-ProvenceAges 50 years+ - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT07843693RecruitingPhase 1
Testing three arthritis drugs in healthy volunteers
This trial tests three arthritis medications in healthy people to understand how safe they are and how the body processes them. It may help in developing future treatments for conditions like rheumatoid arthritis.
Grayslake, IllinoisAges 18–65 - NCT07535645RecruitingPhase 1/Phase 2
Baricitinib for Low Platelet Counts After Bone Marrow Transplant
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07222137RecruitingPhase 3
Baricitinib to delay type 1 diabetes in at-risk people
This trial tests if baricitinib, a pill that calms the immune system, can slow down or delay the onset of type 1 diabetes in children and adults who are at high risk. It is for people whose blood sugar is already starting to rise but who do not yet need insulin.
Santa Barbara, CaliforniaAges 1–35 - NCT07222332RecruitingPhase 3
Baricitinib for new type 1 diabetes to save insulin-making cells
This trial tests if baricitinib, a pill that calms the immune system, can protect the remaining insulin-making cells in people newly diagnosed with type 1 diabetes. If it works, you might keep making some of your own insulin longer.
Aurora, ColoradoAges 1–35 - NCT06936215RecruitingPhase 3
Baricitinib vs methotrexate for skin tightening in scleroderma
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
DhakaAges 18 years+ - NCT06923072RecruitingPhase 2
Baricitinib for neurological Kohlmeier-Degos disease
This trial tests if the drug baricitinib can help people with Degos disease that has affected their brain or nerves. It aims to control inflammation and improve symptoms.
Bethesda, MarylandAges 18–99 - NCT06849908RecruitingPhase 2
Baricitinib for treating intestinal Behçet's disease
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
Beijing, Beijing MunicipalityAges 18–65 - NCT06631287RecruitingPhase 3
Testing baricitinib for persistent long COVID symptoms
This trial tests whether the anti-inflammatory drug baricitinib can improve persistent long COVID symptoms like brain fog, fatigue, and shortness of breath. You may qualify if you had COVID-19 at least 6 months ago and still have bothersome symptoms that affect your daily life.
Tucson, ArizonaAges 18 years+ - NCT06065046RecruitingPhase 2
Baricitinib for traumatic brain bleeding
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
Xi'an, ShaanxiAges 18–80 - NCT05723198RecruitingPhase 3
Baricitinib for severe childhood hair loss from alopecia areata
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Birmingham, AlabamaAges 6–17 - NCT05452564RecruitingPhase 2
Baricitinib to help reduce HIV in the brain
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Atlanta, GeorgiaAges 18–65 - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT03773965RecruitingPhase 3
Baricitinib study for kids with juvenile arthritis
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
RosarioAges 1–18 - NCT05003310Recruiting
Splenic stimulation study for active rheumatoid arthritis
This study tests a treatment that stimulates the spleen to help calm symptoms of active rheumatoid arthritis (RA). It’s mainly for people whose RA has not improved enough after several newer arthritis medicines.
Anniston, AlabamaAges 22–75 - NCT02735707RecruitingPhase 3
Adaptive trial for severe pneumonia care in intensive care
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Jacksonville, FloridaAges 18 years+ - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT07608796RecruitingPhase 2
JAK inhibitor for depression in male football players
This study tests a new medication (a JAK inhibitor) that may reduce brain inflammation and improve depression and thinking in male football players. It aims to see if this treatment helps with mood and cognitive function.
Atlanta, GeorgiaAges 30–55 - NCT07554222RecruitingPhase 1
Safety study of IBI3013 for vitiligo and hair loss
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85 - NCT06768840RecruitingPhase 2/Phase 3
New treatment for active vitiligo, checking blood markers
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
QinaAges 10–75 - NCT07003997RecruitingPhase 2
Targeting inflammation for depression treatment
This trial tests whether a medication that targets inflammation in the body can help relieve depression symptoms. You will have blood tests and an MRI to see how your brain and immune system respond.
Atlanta, GeorgiaAges 25–55 - NCT06977035Recruiting
Nerve study for arthritis patients on baricitinib
This trial checks how the medication baricitinib affects nerves in people with rheumatoid arthritis. It uses a nerve test to see if the drug causes nerve problems.
SohagAges 18–65
What Baricitinib is being studied for
Conditions with recruiting Baricitinib studies.
Common questions
- Are there clinical trials studying Baricitinib?
- Yes. Clin2 currently lists 32 recruiting studies that include Baricitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Baricitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Baricitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Baricitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.